Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection.
We compared the clinical characteristics and outcomes of 100 patients with human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL; HIV-NHL) treated in the highly active antiretroviral therapy era with those of 82 HIV-negative patients with aggressive NHL. The 3-year overall survival (OS) was 37% among patients with HIV-NHL and 74% among HIV-negative patients with NHL (P<.0001). However, the response-adjusted OS was similar in the 2 groups (hazard ratio, 1.4 for HIV-infected patients vs. 1 for HIV-negative patients; P=.24). Therefore, the achievement of complete remission should be the main goal in the treatment of patients with HIV-NHL.
Spina
Michele
M
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.
Carbone
Antonino
A
Vaccher
Emanuela
E
Gloghini
Annunziata
A
Talamini
Renato
R
Cinelli
Roberta
R
Martellotta
Ferdinando
F
Tirelli
Umberto
U
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000150:complications / Q000401:mortality*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000401:mortality*; D008297:Male; D008875:Middle Aged
D019380:Anti-HIV Agents